Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations

Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is an effective treatment for advanced non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations. However, there have been little evidence-based studies of gefitinib in combination with platinum-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical oncology (Northwood, London, England) London, England), 2015-03, Vol.32 (3), p.40, Article 40
Hauptverfasser:	Tamiya, Akihiro, Tamiya, Motohiro, Shiroyama, Takayuki, Saijo, Nobuhiko, Nakatani, Takeshi, Minomo, Shojiro, Tsuji, Taisuke, Takeuchi, Naoko, Omachi, Naoki, Kurata, Kanako, Suzuki, Hidekazu, Okamoto, Norio, Okishio, Kyoichi, Hirashima, Tomonori, Atagi, Shinji
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Disease-Free Survival Drug Combinations Female Hematology Humans Internal Medicine Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Medicine Medicine & Public Health Middle Aged Mutation Oncology Original Paper Oxonic Acid - administration & dosage Pathology Quinazolines - administration & dosage Receptor, Epidermal Growth Factor - genetics Tegafur - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!